Ablexis Announces Licensing Agreement with Allogene Therapeutics

« Back to News

Grants rights to research, develop and commercialize antibodies generated using the AlivaMab Mouse platform

SAN DIEGO, Calif. – December 6, 2018 – Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Allogene Therapeutics, Inc. The license grants Allogene rights to research, develop and commercialize certain AlivaMab antibodies against several targets. Financial terms were not disclosed.

“Ablexis is excited to add Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, as a licensee,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “This agreement with Allogene highlights the potential applications of AlivaMab antibodies in novel drug modalities such as CAR Ts.  We believe our transgenic mouse platform will play an integral role in the continued advancement of the field of immunotherapy.”

The AlivaMab Mouse is designed to enable and optimize the efficient discovery and development of the next generation of human therapeutic antibodies. The platform has been validated for antibody drug discovery by Ablexis and partners in various formats including regular antibodies, bispecifics and CAR Ts and for a range of applications.

About Ablexis, LLC

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis

continues making the AlivaMab Mouse available via non-exclusive licenses.  For more information, visit  For inquiries about licensing AlivaMab Mouse, contact us at

Media Contact:

Christine Quern